Cardiol Therapeutics (CRDL) Earnings Analysis
Cardiol Therapeutics (CRDL) next reports earnings on 2026-08-13, consensus EPS -0.08 USD. Last quarter (2026-05-11) it beat with EPS -0.07 USD vs -0.07 USD est (0%). It has beaten estimates in 7/8 recent quarters (88%). Trailing P/E -4.65.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CRDL next report earnings?
| Next earnings date | 2026-08-13 |
|---|---|
| Consensus EPS estimate | -0.08 USD |
| Revenue estimate | n/a |
CRDL earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-11 | -0.07 USD | -0.07 USD | 0% | Beat |
| 2026-03-30 | -0.05097 USD | -0.09 USD | +43.4% | Beat |
| 2025-11-13 | -0.09 USD | -0.09 USD | 0% | Beat |
| 2025-08-14 | -0.07 USD | -0.11 USD | +36.4% | Beat |
| 2025-05-14 | -0.07 USD | -0.09 USD | +22.2% | Beat |
| 2025-03-31 | -0.07 USD | -0.08 USD | +12.5% | Beat |
| 2024-11-14 | -0.13 USD | -0.1 USD | -30% | Miss |
| 2024-08-12 | -0.07 USD | -0.1 USD | +30% | Beat |
Beat rate: 7/8 (88%) over reported quarters with consensus data.
CRDL valuation and analyst view
| Trailing P/E | -4.65 |
|---|---|
| Trailing EPS | -0.33352 USD |
| Price / book | 8.20 |
| Dividend yield | 0.00% |
| Market cap | 0.14B |
| Analyst consensus | Buy (2 buy / 0 hold / 0 sell) |
Related research pages
Frequently asked questions
When is Cardiol Therapeutics (CRDL)'s next earnings date?
Cardiol Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.08 USD.
Did CRDL beat earnings last quarter?
In its 2026-05-11 report, CRDL posted EPS of -0.07 USD versus a -0.07 USD estimate — a beat of 0%.
What is CRDL's earnings track record?
Over the last 8 reported quarters with consensus data, CRDL beat estimates 7 times (88%).
What is CRDL's current P/E ratio and EPS?
CRDL trades at a trailing P/E of -4.65 on trailing EPS of -0.3335224863778979 USD.
What do analysts rate CRDL?
Analyst consensus is "Buy" across 2 ratings (0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell).